Applied DNA Sciences (NASDAQ:APDN) Lifted to Sell at StockNews.com

StockNews.com upgraded shares of Applied DNA Sciences (NASDAQ:APDN) to a sell rating in a research report report published on Tuesday morning.

Separately, HC Wainwright cut their price target on Applied DNA Sciences from $7.00 to $1.50 and set a buy rating on the stock in a research note on Monday, June 10th.

Applied DNA Sciences Stock Performance

Applied DNA Sciences stock opened at $1.21 on Tuesday. The firm has a market capitalization of $1.19 million, a PE ratio of -0.07 and a beta of 0.37. Applied DNA Sciences has a one year low of $0.31 and a one year high of $27.18. The stock’s 50 day moving average price is $1.03 and its 200 day moving average price is $3.23.

Applied DNA Sciences (NASDAQ:APDN) last posted its earnings results on Thursday, August 8th. The technology company reported $0.47 EPS for the quarter, topping analysts’ consensus estimates of ($0.64) by $1.11. Applied DNA Sciences had a negative net margin of 214.42% and a negative return on equity of 138.41%. The business had revenue of $0.80 million for the quarter, compared to analysts’ expectations of $0.95 million. During the same period in the previous year, the company posted ($4.80) earnings per share. On average, analysts forecast that Applied DNA Sciences will post -1.8 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Applied DNA Sciences stock. AMH Equity Ltd grew its stake in Applied DNA Sciences, Inc. (NASDAQ:APDN) by 46.1% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 540,385 shares of the technology company’s stock after purchasing an additional 170,385 shares during the quarter. AMH Equity Ltd owned approximately 63.57% of Applied DNA Sciences worth $222,000 as of its most recent filing with the SEC. 22.22% of the stock is owned by institutional investors.

About Applied DNA Sciences

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.